Do We Have a Chance to Translate Bench-top Results to the Clinic Adequately on Stroke? An Opinion

A wonderfully wordy opinion that tells you absolutely nothing useful for stroke survivors.
No point in getting the actual article after reading this abstract. I can't even figure out whom this is written for unless it is someone with zero knowledge of stroke.
https://link.springer.com/chapter/10.1007/978-981-10-5804-2_26

• Authors
• Authors and affiliations

• Kristine Edgar DanielyanEmail author

• Kristine Edgar Danielyan
  • 1
  • 2
  Email author

1. 1.H. Buniatian Institute of BiochemistryYerevanArmenia
2. 2.Yerevan State UniversityYerevanArmenia

Chapter

First Online: 22 December 2017

• 14 Downloads

Part of the Translational Medicine Research book series (TRAMERE)

Abstract

Animal models of ischemic, hemorrhagic stroke and transformation certainly have vivid importance for clinical studies and development of thrombolytic as well as neuroprotective drugs. Clear understanding of techniques for every type of stroke modeling highlights naturally impossible adverse effects of the surgery, which might greatly influence the interpretation of final experimental results. There are no stroke models that fully reflect human disease. Infarcts are relatively larger in experimental animals than in humans with strokes. The models are more analogous to massive hemispheric infarcts than to localized strokes such as those in the internal capsule. Every type of animal stroke model is a partial hallmark of clinical picture. Thus, knowledge about the variety of stroke models allows choosing the system, which will serves for testing drugs or compound, predicting effective doses, and evaluating possible adverse effects, pharmacokinatics. Clinical trials might be more informative and successful if benchtop results are clearly delineated and reflect treatment time window, mechanism, and doses.